Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Checkpoint blockade in cancer immunotherapy.

Korman AJ, Peggs KS, Allison JP.

Adv Immunol. 2006;90:297-339. Review.

2.

Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.

Peggs KS, Quezada SA, Allison JP.

Immunol Rev. 2008 Aug;224:141-65. doi: 10.1111/j.1600-065X.2008.00649.x. Review.

PMID:
18759925
3.

Immune checkpoint therapy for non-small-cell lung cancer: an update.

Xia B, Herbst RS.

Immunotherapy. 2016;8(3):279-98. doi: 10.2217/imt.15.123. Epub 2016 Feb 9. Review.

PMID:
26860624
4.

At the bench: preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy.

Intlekofer AM, Thompson CB.

J Leukoc Biol. 2013 Jul;94(1):25-39. doi: 10.1189/jlb.1212621. Epub 2013 Apr 26. Review.

5.

The blockade of immune checkpoints in cancer immunotherapy.

Pardoll DM.

Nat Rev Cancer. 2012 Mar 22;12(4):252-64. doi: 10.1038/nrc3239. Review.

6.

At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.

Callahan MK, Wolchok JD.

J Leukoc Biol. 2013 Jul;94(1):41-53. doi: 10.1189/jlb.1212631. Epub 2013 May 10. Review.

7.

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.

Gubin MM, Zhang X, Schuster H, Caron E, Ward JP, Noguchi T, Ivanova Y, Hundal J, Arthur CD, Krebber WJ, Mulder GE, Toebes M, Vesely MD, Lam SS, Korman AJ, Allison JP, Freeman GJ, Sharpe AH, Pearce EL, Schumacher TN, Aebersold R, Rammensee HG, Melief CJ, Mardis ER, Gillanders WE, Artyomov MN, Schreiber RD.

Nature. 2014 Nov 27;515(7528):577-81. doi: 10.1038/nature13988.

8.

Activity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaques.

Keler T, Halk E, Vitale L, O'Neill T, Blanset D, Lee S, Srinivasan M, Graziano RF, Davis T, Lonberg N, Korman A.

J Immunol. 2003 Dec 1;171(11):6251-9.

9.

CTLA-4: negative regulator of the immune response and a target for cancer therapy.

Keilholz U.

J Immunother. 2008 Jun;31(5):431-9. doi: 10.1097/CJI.0b013e318174a4fe. Review.

PMID:
18463542
11.

CTLA-4 blockade: autoimmunity as treatment.

Kapadia D, Fong L.

J Clin Oncol. 2005 Dec 10;23(35):8926-8. Epub 2005 Oct 3. No abstract available.

PMID:
16204008
12.

Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.

Weber J.

Semin Oncol. 2010 Oct;37(5):430-9. doi: 10.1053/j.seminoncol.2010.09.005. Review.

PMID:
21074057
13.

Future directions in tumor immunotherapy: CTLA4 blockade.

Gulley JL, Dahut WL.

Nat Clin Pract Oncol. 2007 Mar;4(3):136-7. No abstract available.

PMID:
17327854
14.

Antibody Blockade of Semaphorin 4D Promotes Immune Infiltration into Tumor and Enhances Response to Other Immunomodulatory Therapies.

Evans EE, Jonason AS Jr, Bussler H, Torno S, Veeraraghavan J, Reilly C, Doherty MA, Seils J, Winter LA, Mallow C, Kirk R, Howell A, Giralico S, Scrivens M, Klimatcheva K, Fisher TL, Bowers WJ, Paris M, Smith ES, Zauderer M.

Cancer Immunol Res. 2015 Jun;3(6):689-701. doi: 10.1158/2326-6066.CIR-14-0171. Epub 2015 Jan 22.

15.

Inhibitors of B7-CD28 costimulation in urologic malignancies.

Thompson RH, Kwon ED, Allison JP.

Immunotherapy. 2009 Jan;1(1):129-39. doi: 10.2217/1750743X.1.1.129.

16.

Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma.

Tykodi SS.

Immunotherapy. 2013 Jun;5(6):607-19. doi: 10.2217/imt.13.39. Review.

PMID:
23725284
17.

Simultaneous blockade of multiple immune system inhibitory checkpoints enhances antitumor activity mediated by interleukin-15 in a murine metastatic colon carcinoma model.

Yu P, Steel JC, Zhang M, Morris JC, Waldmann TA.

Clin Cancer Res. 2010 Dec 15;16(24):6019-28. doi: 10.1158/1078-0432.CCR-10-1966. Epub 2010 Oct 5.

19.

Current developments with peptide-based human tumor vaccines.

Khazaie K, Bonertz A, Beckhove P.

Curr Opin Oncol. 2009 Nov;21(6):524-30. doi: 10.1097/CCO.0b013e328331a78e. Review.

PMID:
19770763
20.

The role of antigen-specific and non-specific immunotherapy in the treatment of cancer.

Monjazeb AM, Hsiao HH, Sckisel GD, Murphy WJ.

J Immunotoxicol. 2012 Jul-Sep;9(3):248-58. doi: 10.3109/1547691X.2012.685527. Epub 2012 Jun 26. Review.

PMID:
22734880

Supplemental Content

Support Center